The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1447
July 21, 2014
View Complete Issue         Table of Contents 2019 
Oral Propranolol (Hemangeol) for Infantile Hemangioma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oral Propranolol (Hemangeol) for Infantile Hemangioma
July 21, 2014 (Issue: 1447)
The FDA has approved an oral solution of the nonselective beta-adrenergic blocker propranolol (Hemangeol – Pierre Fabre) for treatment of proliferating infantile hemangiomas.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Oral Propranolol (Hemangeol) for Infantile Hemangioma
Article code: 1447c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.